CEO George Frodsham will showcase their groundbreaking Magnetic Blood Filtration technology to over 500 healthcare companies and venture capitalists.

MediSieve's preclinical and first-in-human safety study on the Magnetic Blood Filtration gets published in Nature Scientific Reports.

Dr George Frodsham, CEO of MediSieve, was invited as a panelist at the Jawdrop Life Sciences Summit to discuss ageing, pandemics, and antimicrobial resistance alongside other distinguished experts.

MediSieve is accepted to a highly selected RSC ecosystem of deeptech ventures.

MediSieve announces Dr. Alessandro Falcone, with a distinguished background in Oncology R&D at AstraZeneca and previous roles at GSK and Novartis, as its new board member.

The campaign features a unique Tube map naming stations after prominent engineers, in celebration of the National Engineering Day.

MediSieve's Phase I collaborative work with Radboud Medical Centre was recognised at the Dutch Anaesthesiology Association event.

At the heart of the gallery are stories from more than 60 engineers, working in a broad range of industries, such as biotech, farming, fashion, and robotics.

MediSieve achieves second place in the Biotech category of the EIT Health Catapult held at Bits & Pretzels in Munich.

Please send your CV and a cover letter explaining what you can bring to MediSieve to jobs@medisieve.co.uk.

Magnetic Blood Filtration Platform shown to be safe and well tolerated, with no serious adverse events.

Radboud University Medical Center is Conducting Safety Evaluation of MediSieve’s System for the Treatment of Acute Hyperinflammation.

Radboud University Medical Center will perform the first trial of the Novel Magnetic Haemoflitration System.

MediSieve, a biotech company that has developed an innovative blood filtration device, receives recognition and approval from the industry.

The company has entered an exciting partnership with the Health Tech World to introduce George and his vision for the future.

MediSieve has been busy presenting and demonstrating its technology to some of the world's leading investors throughout March.

In March the company engaged and connected with the communities of UCL and that of the Royal Academy of Engineering by participating in their events.

MediSieve’s first product targets IL-6 cytokine to treat various hyperinflammation condition like Sepsis, COVID-19, and Cytokine Release Syndrome.

Award winning company MediSieve is set to start their first-in-man clinical trials in the first quarter of 2022.

MediSieve is presenting virtually at the Biotech Showcase™ 2022 conference.

MediSieve was selected as the Overall Champion of the 2021 Super Connect for Good Competition organised by Empact Ventures and Hays.

MediSieve presented the company’s journey at the launch of LBS's I2M Programme and later listened to an excellent panel with LBS alumni.

MyBiotech GmbH is MediSieve's production partner, collaborating with the company to validate the manufacture of the Beads.

Neil brings to MediSieve a 40-year track record in quality and regulatory affairs.

Nikkiso Medical has graciously provided MediSieve with their PureADJUST hemoperfusion pump as part of an ongoing collaboration.

This investment will fund first-in-man trials investigating the safety and efficacy of the company’s pivotal IL-6 product.

MediSieve participated in the Life Sciences RoundTable alongside Imperial College London and Novartis.

MediSieve’s continues accelerating the development of it research programmes with the expansion of the lab space and the recruitment of two interns.

MediSieve has been promoted to being a Gold Company within the EIT Health Investor Network, achieving the highest possible rank.

The expansion enabled MediSieve to have full control over safety and equipment to meet the company's R&D needs

MediSieve announced the receipt of a grant from the UK Research and Innovation (UKRI) to support first-in-man trials of its pivotal IL-6-driven hyperinflammation programme.

MediSieve welcomed Cristina Piñel Neparidze and Danny Gold as new team members.

Product | People | Potential article series of ADLIB released an interview with MediSieve's CEO George Frodsham

Throughout September 2020 MediSieve took part in UK Sepsis Trust's initiative Cycle4Sepsis.

MediSieve won the regional round out of 42 start-ups in the EIT Health Catapult Semi-finals.

MediSieve has recently shared its mission and latest research developments with leading media agencies.

Dr Cristina Blanco-Andujar shared her thoughts on the importance of gender diversity in engineering.

MediSieve was accepted onto the London & Partners’ Business Growth Programme.

MediSieve has joined a 10-week data analysis program run by the London Business School,

The team focused its activities on investigating how to help treat COVID-19 patients more effectively.

The current pandemic is a stark reminder to us all of the importance of our work and its potential impact.

MediSieve has finally received the second patent (Patent number US10639602B2) for the Magnetic Mixing device in the US

If you missed it, before Christmas, we announced that Dr George Frodsham had been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.

Dr George Frodsham has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.

MediSieve was selected as the most innovative startup at BioFit event in Marseille.

It’s been a very busy but exciting couple of months for us. You may have seen us in the national or industry news.

Medical device company MediSieve Ltd, has been announced as a winner of the ‘Breakthrough Medical or Healthcare Device Award’ in the Beanstalks competition 2019.

Founder and CEO, Dr George Frodsham, speaks to the Telegraph on the birth and journey of MediSieve.

MediSieve held a charity bake sale to support the UK Sepsis Trust on the World Sepsis Day.

MediSieve was shortlisted for the final round of 2019 Emerging Technology Competition, run by the Royal Society of Chemistry.

The summer holidays may be almost over, but here at MediSieve, we’ve been keeping very busy.

Dr George Frodsham has won the Early Career Impact Award at the BBSRC Innovator of the Year Awards 2019.

Over this year MediSieve has grown from a four-people start-up into a diverse team of professionals with various expertise.

The patent for MediSieve’s magnetic blood filter has now been granted in the United States.

MediSieve has won the highly competitive award category of Investment Achievement at the the annual Mayor of London Awards.

As we support #WorldMalariaDay today, take a look at our animation.

MediSieve is a finalist in the Investment category of this year’s MedTech London Awards.

MediSieve is highlighting its work for World Malaria Day on April 25 - as figures show 435,000 people died from the disease in 2017.

MediSieve selected at MedCity's Company of the Month. MedCity support and grow the world-leading life sciences ecosystem of the Greater South East of England.

MediSieve's CEO Dr George Frodsham provides inspiration to aspiring scientific entrepreneurs

MediSieve is delighted to announce that it is receiving two grants from Innovate UK, worth a total of around £1.56m.

Nominated by Upstream, MediSieve made it to the shortlist of this year's Hammersmith and Fulham Brilliant Business Awards.

Dr Cristina Blanco Andujar, the Head of R&D at the innovative medical device company, MediSieve, has been awarded a position on the Royal Academy of Engineering's prestigious SME Leaders Programme.

MediSieve wins 1st runner up at prestigious Boston Biotech Week start up competition

MediSieve has been announced as a finalist in the inaugural Medtech Insight Awards 2018, in the category of Innovative Team of the Year.

MediSieve has been included in the round-up of the most exciting medical technology companies who presented at the event.

MediSieve are happy to announce the company has received over £1.75 million in funding.

MediSieve, the company behind a revolutionary magnetic sieve that filters out malaria-infected cells directly from a patient’s bloodstream, is developing new methods to fight leukaemia.

Award-winning medical technology company MediSieve have been awarded a grant worth £150,000 by the National Institute of Health Research.

Award-wining medical technology start-up MediSieve has announced its move to prestigious new offices, capping a period of rapid growth, as well as adding a new team member.

MediSieve have recently been announced winners of the CMS Healthcare Startup of the Year Award 2017 in the Beanstalks competition.

MediSieve has recently welcomed William Twigger (ex Baxter and First Water) as their new Product Engineer

On September 27, 2017, George Frodsham, founder and CEO of MediSieve, is presenting at the TCT Show.

The team behind the medical device start-up MediSieve have been nominated for their potentially life-saving magnetic blood filtration device in the Healthcare Application category of the TCT Magazine 2017 Awards.